Liver Cancer Therapeutics Market Report 2025

The liver cancer therapeutics market size has grown rapidly in recent years. It will grow from $2.52 billion in 2024 to $2.94 billion in 2025 at a compound annual growth rate (CAGR) of 16.8%. The growth in the historic period can be attributed to increasing funding from government and non-profits, rising healthcare expenditure globally, expanding health insurance coverage in developing countries, aging global population, increasing prevalence of obesity and diabetes.

The liver cancer therapeutics market size is expected to see rapid growth in the next few years. It will grow to $5.45 billion in 2029 at a compound annual growth rate (CAGR) of 16.7%. The growth in the forecast period can be attributed to rising global incidence of liver cancer, high prevalence of hepatitis B and C infections, increase in alcohol-related liver disease, rising cases of non-alcoholic fatty liver disease, growing adoption of immunotherapy approaches. Major trends in the forecast period include integration of AI and ML in drug discovery, use of big data and real-world evidence in trials, development of advanced imaging technologies, adoption of minimally invasive diagnostic tools, telemedicine and digital health in oncology follow-up care.

The forecast of 16.7% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade tensions could hinder U.S. oncology centers by inflating prices of tyrosine kinase inhibitors and immune checkpoint blockers developed in Switzerland and South Korea, resulting in limited treatment options and higher hepatocellular carcinoma management costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The increasing incidence of hepatitis B infections is expected to drive the growth of the liver cancer therapeutics market. Hepatitis B is a viral disease caused by the hepatitis B virus (HBV), primarily affecting the liver and potentially leading to both acute and chronic health issues, including liver cancer. The rise in hepatitis B infections is partially fueled by the growing use of injection drugs, which spread the virus through the sharing of contaminated needles and syringes. Liver cancer therapeutics are essential for managing hepatitis B infections, as chronic infection can result in ongoing liver inflammation and cellular damage, significantly raising the risk of malignant liver conditions over time. For example, a report published by the World Health Organization (WHO) in April 2024 indicated that in 2022, over 254 million people globally were living with hepatitis B, with 1.2 million new cases recorded. Hepatitis B was also responsible for 83% of the 1.3 million viral hepatitis-related deaths worldwide. Consequently, the rising incidence of hepatitis B infections will accelerate the growth of the liver cancer therapeutics market.

Innovative therapies are driving growth in the liver cancer treatment market, particularly through advancements in immunotherapy. Leading companies in the liver cancer therapeutics market are focusing on developing cutting-edge treatments, such as prescription immunotherapy drugs, to offer long-lasting effects. These medications work by enhancing or suppressing the body’s immune system to fight specific diseases, including cancer or chronic infections, by targeting and modulating immune responses. For example, in April 2025, Bristol Myers Squibb, a U.S.-based biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had approved Opdivo (nivolumab) and Yervoy (ipilimumab) for adult patients with hepatocellular carcinoma (HCC), the most common type of primary liver cancer, either incurable or metastatic, as a first-line treatment. The approval was based on the results of the global Phase 3 randomized, open-label CheckMate-9DW trial, which showed that patients with metastatic or incurable HCC who had not previously received systemic therapy and were randomized to receive Opdivo plus Yervoy along with a tyrosine kinase inhibitor (lenvatinib or sorafenib) experienced statistically significant improvements in overall survival (OS) and overall response rate (ORR) compared to the comparator group. This combination therapy was the only one supporting an FDA approval with superior results in this setting.

In September 2023, Coherus BioSciences Inc., a U.S.-based biopharmaceutical company, acquired Surface Oncology Inc. for an undisclosed amount. This acquisition strengthens Coherus' immuno-oncology pipeline, which now includes four distinct clinical-stage assets toripalimab (anti-PD-1), casdozokitug (IL-27-targeted), CHS-114 (CCR8-targeted), and CHS-006 (TIGIT-targeted). The focus of development will be on achieving breakthrough survival benefits for cancer patients, aiming to surpass the efficacy of current chemotherapy combined with checkpoint inhibitor regimens. Surface Oncology Inc. is a US-based company, focusing on developing therapeutics for liver cancer.

Major players in the liver cancer therapeutics market are Pfizer Inc., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Novartis AG, Bayer AG, Sanofi SA, Bristol-Myers Squibb, AstraZeneca PLC, Amgen Inc., Eli Lilly and Company, Gilead Sciences Inc., Regeneron Pharmaceuticals Inc., Eisai Co. Ltd., Ipsen, Exelixis Inc., BeiGene Ltd., Hutchmed, Celgene Corporation, Zymeworks Inc., Can-Fite BioPharma, and Onyx Pharmaceuticals Inc.

North America was the largest region in the liver cancer therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in liver cancer therapeutics report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the liver cancer therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The liver cancer therapeutics market consists of revenues earned by entities by providing services such as diagnostics and screening, personalized treatment planning, minimally invasive procedures, and supportive care services. The market value includes the value of related goods sold by the service provider or included within the service offering. The liver cancer therapeutics market also includes sales of drug delivery systems, diagnostic kits, biologics and supportive medications. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report’s Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sudden escalation of U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the pharmaceutical sector. Companies are grappling with higher costs on imported active pharmaceutical ingredients (APIs), glass vials, and laboratory equipment - many of which have limited alternative sources. Generic drug manufacturers, already operating with minimal profit margins, are particularly affected, with some scaling back production of low-margin medications. Biotech firms are also experiencing delays in clinical trials due to shortages of specialized reagents linked to tariffs. In response, the industry is shifting API production to regions like India and Europe, building up inventory reserves, and advocating for tariff exemptions on essential medicines.

The liver cancer therapeutics market research report is one of a series of new reports that provides liver cancer therapeutics market statistics, including liver cancer therapeutics industry global market size, regional shares, competitors with a liver cancer therapeutics market share, detailed liver cancer therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the liver cancer therapeutics industry. This liver cancer therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Liver cancer therapeutics involve a range of treatments designed to manage abnormal cell growth in the liver, a vital organ responsible for essential metabolic and detoxification functions. These therapies aim to target, control, or eradicate harmful cellular activity while preserving as much healthy tissue as possible.

The main types of liver cancer therapeutics include treatments for hepatocellular carcinoma, cholangiocarcinoma, hepatoblastoma, and other liver cancers. Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer, originating in the liver's hepatocytes (the primary liver cells). It is a leading cause of cancer-related deaths worldwide, especially in regions with high rates of chronic liver diseases including hepatitis B, hepatitis C, alcohol-related liver disease, and cirrhosis (liver scarring). Treatments for HCC include targeted therapy, immunotherapy, chemotherapy, radiation therapy, and others. These therapies are available through hospital pharmacies, retail pharmacies, and online pharmacies, and are used by a wide range of patients, including both adults and children.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.